Analisis Keuangan Saham SEELQ - Seelos Therapeutics, Inc. (OTCPK) Stock

Seelos Therapeutics, Inc.
US ˙ OTCPK

Gambaran Umum
Seelos Therapeutics, Inc., based in the United States, operates within the biopharmaceutical industry and focuses on developing therapies for central nervous system disorders and rare diseases. A key element of its project portfolio includes advanced clinical-stage assets targeted at psychiatric and movement disorders, exemplifying its commitment to addressing unmet medical needs. Noteworthy projects include SLS-002 for acute suicidal ideation and behavior in major depressive disorder, and SLS-005 in Huntington's disease, both under expedited regulatory pathways due to their potential significance in therapy. The company’s strategic approach combines repositioning known entities with new mechanistic insights, aiming to streamline the path toward clinical relevance and market entry.
Skor Kualitas, Nilai, dan Momentum

Kartu ini menunjukkan skor Kualitas, Nilai, dan Momentum untuk perusahaan tersebut.

Kualitas

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Nilai

Model penilaian eksklusif yang memberi peringkat pada perusahaan berdasarkan valuasi relatifnya. Skor berkisar antara 0 hingga 100, dengan 100 sebagai yang paling diremehkan nilainya.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Sentimen Dana

Skor Sentimen Dana (sebelumnya dikenal sebagai Skor Kepemilikan) adalah model kuantitatif eksklusif yang memberi peringkat pada perusahaan berdasarkan tingkat akumulasi kepemilikan.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Laporan Laba Rugi: Pendapatan, Laba Operasional, Laba Bersih
  • Nilai revenue untuk Seelos Therapeutics, Inc. per 2024 Jun 30 adalah 2.01 MM.
  • Nilai operating income untuk Seelos Therapeutics, Inc. per 2024 Jun 30 adalah -29.81 MM.
  • Nilai net income untuk Seelos Therapeutics, Inc. per 2024 Jun 30 adalah 4.09 MM.
Period End (TTM) Revenue (MM) Operating Income (MM) Net Income (MM)
2024-06-30 2.01 -29.81 4.09
2024-03-31 1.97 -37.62 -27.11
2023-12-31 2.20 -40.50 -37.88
2023-09-30 1.55 -50.74 -51.09
2023-06-30 1.14 -55.55 -81.19
2023-03-31 0.81 -65.84 -72.96
2022-12-31 -70.92 -73.53
2022-09-30 -80.03 -82.14
2022-06-30 -73.53 -73.35
2022-03-31 -59.07 -60.93
2021-12-31 -61.67 -66.05
2021-09-30 -40.14 -45.24
2021-06-30 -33.31 -38.51
2021-03-31 -29.86 -33.38
2020-12-31 -18.76 -19.10
2020-09-30 0.00 -25.44 -23.31
Laporan Laba Rugi: EPS
  • earnings per share basic untuk Seelos Therapeutics, Inc. pada 2024 Jun 30 adalah 47.06.
  • laba per saham yang terdilusi untuk Seelos Therapeutics, Inc. pada 2024 Jun 30 adalah 47.11.
Period End (TTM) Earnings Per Share Basic Earnings Per Share Diluted
2024-06-30 47.06 47.11
2024-03-31 -481.09 -479.94
2023-12-31 -989.53 -989.44
2023-09-30 -1,610.89 -2,473.13
2023-06-30 -2,719.96 -2,720.03
2023-03-31 -2,591.24 -2,591.36
2022-12-31 -2,654.56 -2,654.72
2022-09-30 -2,988.83 -2,999.55
2022-06-30 -2,695.19 -2,695.19
2022-03-31 -2,339.62 -2,339.62
2021-12-31 -2,790.49
2021-09-30 -2,216.73 -2,216.73
2021-06-30 -2,293.32 -2,293.32
2021-03-31 -2,396.11 -2,396.11
2020-12-31 -1,638.45
2020-09-30
Arus Kas: Operasi, Investasi, Pendanaan
  • Nilai cash from operating activities untuk Seelos Therapeutics, Inc. per 2024 Jun 30 adalah -13.27 MM.
  • Nilai kas dari aktivitas pendanaan untuk Seelos Therapeutics, Inc. per 2024 Jun 30 adalah 7.72 MM.
Period End (TTM) Cash From Operating Activities (MM) Cash From Investing Activities (MM) Cash From Financing Activities (MM)
2024-06-30 -13.27 7.72
2024-03-31 -18.21 4.67
2023-12-31 -23.91 11.38
2023-09-30 -35.09 7.16
2023-06-30 -40.42 5.01
2023-03-31 -54.91 7.19
2022-12-31 -61.60 -1.60
2022-09-30 -66.85 20.53
2022-06-30 -66.29 20.34
2022-03-31 -54.79 77.87
2021-12-31 -48.99 112.07
2021-09-30 -33.98 102.76
2021-06-30 -27.66 109.00
2021-03-31 -25.74 51.74
2020-12-31 -20.91 26.31
2020-09-30 -22.70 15.44
Metrik Penilaian: PE, PriceToBook, PriceToTBV
P/Book
The current closing price divided by the book value per share.
P/TBV
The current price divided by the tangible book value per share.
Period End (TTM) p/e P/Book P/TBV
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
Metrik Penilaian: EBitToEv, EBit3YrAvgToEv
Period End (TTM) EBIT/EV EBIT (3y)/EV
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
Efektivitas Manajemen
  • roa untuk Seelos Therapeutics, Inc. pada 2024 Jun 30 adalah -1.15.
Period End (TTM) ROA ROE ROIC (Tingkat Pengembalian Investasi Modal) CROIC OCROIC
2024-06-30 -1.15
2024-03-31 -1.67
2023-12-31 -1.26 -6.48
2023-09-30 -1.54 -3.10
2023-06-30 -1.54 -3.10
2023-03-31 -1.03 -1.60
2022-12-31 -1.01 -1.13 -2.80 -1.58 -2.28
2022-09-30 -1.01 -1.13 -2.80 -1.58 -2.28
2022-06-30 -0.81 -0.89 -1.61 -1.01 -1.46
2022-03-31 -1.47 -2.46 -0.94 0.36 -0.85
2021-12-31 -3.78 -25.68 -0.87 0.83 -0.64
2021-09-30 -4.58 -6.76 -0.62 0.94 -0.47
2021-06-30 -4.96 -10.39 -0.47 0.98 -0.33
2021-03-31 -2.36 -4.93 -1.10 0.86 -0.85
2020-12-31 -1.72 -1.55 0.44 -1.70
2020-09-30 -1.44 -2.25 -3.41 -1.06 -3.32
Gross Margins
  • marjin kotor untuk Seelos Therapeutics, Inc. pada 2024 Jun 30 adalah -13.17.
  • marjin bersih untuk Seelos Therapeutics, Inc. pada 2024 Jun 30 adalah -13.74.
  • marjin operasi untuk Seelos Therapeutics, Inc. pada 2024 Jun 30 adalah -19.06.
Margin Kotor
The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
Margin Keuntungan Bersih
Margin Bersih (juga dikenal sebagai Margin Keuntungan) adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Bersih. Perhitungannya adalah Pendapatan Bersih / Pendapatan.
Margin Operasi
Margin Operasi adalah rasio pendapatan yang tersisa setelah dikurangi Pendapatan Operasi. Perhitungannya adalah Pendapatan Operasi / Pendapatan.
Period End (TTM) Margin Kotor Margin Keuntungan Bersih Margin Operasi
2024-06-30 -13.17 -13.74 -19.06
2024-03-31 -12.67 -17.20 -18.38
2023-12-31 -45.64 -32.96 -32.74
2023-09-30 13.40 -70.97 -48.56
2023-06-30 13.40 -70.97 -48.56
2023-03-31 6.37 -90.30 -81.48
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
Pengenal dan Deskriptor
Kunci Indeks Pusat (CIK)1017491
Grupong Pang-industriya
SIC 2834 - Pharmaceutical Preparations
Other Listings
DE:NXE
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista